Showing results (121-130 of 348) with videos related to
Sort By:
Pageof 35
Neurodegenerative Disease Management|July 22, 2022
The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summaryHarald Hampel, Aya Elhage, Leslie M Shaw, et al.Journal of Alzheimer'S Disease : JAD|January 7, 2017
A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease RiskGemma Tell-Marti, Joan Anton Puig-Butille, Miriam Potrony, et al.Alzheimer'S Research & Therapy|February 13, 2025
Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementiaConstance Delaby, Daniel Alcolea, Germain Busto, et al.Research Square|January 7, 2025
Impaired Cerebrospinal Fluid Lipoprotein-Mediated Cholesterol Delivery to Neurons in Alzheimer's DiseaseCarla Borràs, Marina Canyelles, David Santos, et al.Annals of Clinical and Translational Neurology|August 30, 2019
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on LumipulseDaniel Alcolea, Jordi Pegueroles, Laia Muñoz, et al.Scientific Reports|May 26, 2019
Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's diseaseEstrella Morenas-Rodríguez, Daniel Alcolea, Marc Suárez-Calvet, et al.Scientific Reports|August 15, 2020
Evaluation of biochemical and hematological parameters in adults with Down syndromeDavid de Gonzalo-Calvo, Isabel Barroeta, Madalina Nicoleta Nan, et al.Stroke|January 4, 2014
Prognostic value of plasma β-amyloid levels in patients with acute intracerebral hemorrhageJoan Martí-Fàbregas, Raquel Delgado-Mederos, Rebeca Marín, et al.Annals of Neurology|July 26, 2021
Metabolite Signature of Alzheimer's Disease in Adults with Down SyndromeVictor Montal, Isabel Barroeta, Alexandre Bejanin, et al.Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's diseaseAlain D Dekker, Yannick Vermeiren, Maria Carmona-Iragui, et al.Pageof 35